Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Further, the company provides thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.
Navigating Challenges | Despite strong positioning, Waters faces risks from sector dependency and intense competition, necessitating continuous innovation to maintain market leadership |
Financial Outlook | Waters targets 6% to high single-digit growth in its Long Range Plan, with analysts forecasting EPS of $12.84 for FY2025 and price targets ranging from $360 to $460 |
Strategic Acquisition | Wyatt Technology purchase enhances Waters' biologics characterization capabilities, potentially expanding market reach and driving innovation |
Biotech Boom Catalyst | Waters Corporation poised for growth amid surging biologics and GLP-1 markets, leveraging its strong position in pharmaceutical QA/QC processes |
Metrics to compare | WAT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipWATPeersSector | |
---|---|---|---|---|
P/E Ratio | 29.9x | −0.1x | −0.5x | |
PEG Ratio | −24.93 | 0.12 | 0.00 | |
Price / Book | 10.4x | 1.7x | 2.6x | |
Price / LTM Sales | 6.4x | 1.5x | 2.9x | |
Upside (Analyst Target) | 22.1% | 61.5% | 66.0% | |
Fair Value Upside | Unlock | 20.3% | 10.6% | Unlock |